{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:53:09Z","timestamp":1781610789813,"version":"3.54.5"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100026234","name":"Big Ten Academic Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026234","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Steroid-resistant nephrotic syndrome (SRNS) in children carries a poor prognosis, and recent discoveries implicate anti-nephrin autoantibodies (ANABs) as mediators of podocyte injury. Lipoprotein apheresis, originally developed for familial hypercholesterolemia, has been explored as rescue therapy in refractory SRNS, but its immunologic effects remain uncertain. This case demonstrates a decline in ANAB titers accompanied by clinical improvement following lipoprotein apheresis.<\/jats:p>\n                  <jats:p>We report a 7-year-old male of Afro-Caribbean descent with biopsy findings consistent with minimal change disease and punctate IgG staining who presented with steroid-resistant nephrotic syndrome. He was unresponsive to tacrolimus, rituximab, mycophenolate mofetil, and five therapeutic plasma exchange sessions, and developed severe anasarca requiring extracorporeal ultrafiltration. Compassionate-use lipoprotein apheresis was initiated. Twelve sessions were performed over about ten weeks. Serial plasma ANAB testing showed a marked decrease with lipoprotein apheresis. Clinically, urine output increased, edema resolved, and ultrafiltration was discontinued about seven weeks after the final session, although nephrotic-range proteinuria persisted.<\/jats:p>\n                  <jats:p>This case highlights the potential immunomodulatory role of lipoprotein apheresis in ANAB-mediated podocytopathy. Improvement despite lack of response to therapeutic plasma exchange suggests that lipoprotein apheresis may remove certain antibodies and immune complexes more efficiently compared to conventional therapeutic plasma exchange. Serial ANAB monitoring provided a biomarker correlating with treatment response. Controlled studies are needed to clarify the mechanisms and define the role of lipoprotein apheresis in ANAB\u2013positive SRNS patients.<\/jats:p>","DOI":"10.1093\/joneph\/aajag028","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:40:40Z","timestamp":1770122440000},"page":"408-413","source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein apheresis for anti-nephrin antibody\u2013positive steroid-resistant nephrotic syndrome: a\u00a0pediatric case report"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9350-1004","authenticated-orcid":false,"given":"Rayan","family":"Terkawi","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago\/Northwestern University , Chicago, IL ,","place":["United States"]},{"name":"Pediatric Nephrology, Holtz Children's Hospital\/University of Miami , Miami, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Timmer","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Holtz Children's Hospital\/University of Miami , Miami, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Weins","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqin","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Miami Medical Group, Miller School of Medicine , Miami, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Mattiazzi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Katz Family Division of Nephrology and Hypertension and Miami Transplant Institute, University of Miami , Miami, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Abitbol","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Holtz Children's Hospital\/University of Miami , Miami, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chryso","family":"Katsoufis","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Holtz Children's Hospital\/University of Miami , Miami, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"2026061607061181700_aajag028-B1","volume-title":"Minimal Change Disease","author":"Zamora","year":"2023"},{"key":"2026061607061181700_aajag028-B2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/ASN.2021060794\/-\/DCSUPPLEMENTAL","article-title":"Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology","volume":"33","author":"Watts","year":"2022","journal-title":"J Am Soc Nephrol."},{"key":"2026061607061181700_aajag028-B3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/FENDO.2018.00302","article-title":"Nephrin signaling in the podocyte: an updated view of signal regulation at the slit diaphragm and beyond","volume":"9","author":"Martin","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026061607061181700_aajag028-B4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMOA2314471","article-title":"Autoantibodies targeting nephrin in podocytopathies","volume":"391","author":"Hengel","year":"2024","journal-title":"N Engl J Med."},{"key":"2026061607061181700_aajag028-B5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.kint.2025.02.028","article-title":"Anti-nephrin antibodies in adult Chinese patients with minimal change disease and primary focal segmental glomerulosclerosis","volume":"108","author":"Shu","year":"2025","journal-title":"Kidney Int"},{"key":"2026061607061181700_aajag028-B6","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/S00467-025-06705-5","article-title":"Outcomes and prognostic factors in childhood-onset steroid-resistant nephrotic syndrome: a retrospective single-center study","volume":"40","author":"Zerkowitz","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"2026061607061181700_aajag028-B7","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1046\/j.1523-1755.1999.07102.x","article-title":"Lipopheresis in the nephrotic syndrome","volume":"56","author":"Brunton","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"2026061607061181700_aajag028-B8","volume-title":"Lipoprotein Apheresis","author":"Moriarty","year":"2023"},{"key":"2026061607061181700_aajag028-B9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/S00467-018-4061-9","article-title":"An update on LDL apheresis for nephrotic syndrome","volume":"34","author":"Raina","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2026061607061181700_aajag028-B10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/MNH.0B013E32833AA4AC","article-title":"Renal lipid metabolism and lipotoxicity","volume":"19","author":"Bobulescu","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026061607061181700_aajag028-B11","doi-asserted-by":"publisher","first-page":"12174","DOI":"10.3390\/IJMS252212174","article-title":"Detailed pathophysiology of minimal change disease: insights into podocyte dysfunction, immune dysregulation, and genetic susceptibility","volume":"25","author":"Roman","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026061607061181700_aajag028-B12","doi-asserted-by":"publisher","first-page":"CD005425","DOI":"10.1002\/14651858.CD005425.PUB2","article-title":"Lipid-lowering agents for nephrotic syndrome","volume":"2013","author":"Kong","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026061607061181700_aajag028-B13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/1744-9987.12056","article-title":"Proteomic analysis of proteins eliminated by low-density lipoprotein apheresis","volume":"18","author":"Yuasa","year":"2014","journal-title":"Ther Apher Dial."},{"key":"2026061607061181700_aajag028-B14","doi-asserted-by":"publisher","first-page":"103675","DOI":"10.1016\/j.transci.2023.103675","article-title":"Basic principles of therapeutic plasma exchange","volume":"62","author":"Weinstein","year":"2023","journal-title":"Transfus Apher Sci."},{"key":"2026061607061181700_aajag028-B15","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.ekir.2025.02.017","article-title":"Treatment of nephrotic syndrome with antinephrin antibodies using plasmapheresis, rituximab, and mycophenolate mofetil","volume":"10","author":"Takizawa","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026061607061181700_aajag028-B16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/1744-9987.12356","article-title":"Proteomics approach identifies factors associated with the response to low-density lipoprotein apheresis therapy in patients with steroid-resistant nephrotic syndrome","volume":"20","author":"Kuribayashi-Okuma","year":"2016","journal-title":"Ther Apher Dial."}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/2\/408\/68018320\/aajag028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/2\/408\/68018320\/aajag028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:12:38Z","timestamp":1781608358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/2\/408\/8650410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,9]]},"published-print":{"date-parts":[[2026,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag028","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]}}}